Recombinant CBR1 anticorps

N° du produit ABIN7880172

L’anticorps anti-CBR1 Monoclonal Lapin est utilisé pour la détection de CBR1 dans des échantillons de Humain. Il a été validé pour WB, IHC, ICC et IF.

Aperçu rapide pour Recombinant CBR1 anticorps (ABIN7880172)

Antigène: CBR1 (Carbonyl Reductase 1 (CBR1))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp CBR1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)

Clone: 30C98

Détail du produit anti-CBR1 anticorps

Fonction: CBR1 Antibody / Carbonyl reductase 1

Purification: Affinity-chromatography

Immunogène: A synthesized peptide derived from human CBR1 was used as the immunogen for the CBR1 antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the CBR1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store the CBR1 antibody at -20oC.

Détails sur CBR1

Antigène: CBR1 (Carbonyl Reductase 1 (CBR1))

Autre désignation: CBR1

Sujet: CBR1 antibody detects Carbonyl reductase 1, encoded by the CBR1 gene. Carbonyl reductase 1 is an NADPH dependent enzyme that catalyzes the reduction of carbonyl containing compounds to their corresponding alcohols. This enzyme is part of the short chain dehydrogenase/reductase family and has a broad substrate spectrum, including xenobiotics, endogenous prostaglandins, and pharmacological agents. CBR1 antibody provides a valuable tool for studying drug metabolism, detoxification, and cellular defense mechanisms against reactive carbonyl species.

Carbonyl reductase 1 contributes to the metabolism of anthracycline drugs such as doxorubicin, converting them to less active alcohol metabolites. While this reduces anticancer activity, it also influences drug toxicity, particularly cardiotoxicity. Research with CBR1 antibody has been central to understanding interindividual variability in anthracycline metabolism and its impact on therapeutic outcomes. CBR1 also reduces prostaglandins and quinones, helping regulate inflammatory responses and oxidative stress signaling.

CBR1 has been linked to cancer, cardiovascular disease, and neurodegeneration. Overexpression has been reported in several tumors, where it may promote resistance to chemotherapy. Conversely, genetic polymorphisms in the CBR1 gene influence enzymatic activity and alter susceptibility to drug side effects. Using CBR1 antibody, researchers have demonstrated its tissue specific expression, with high levels in liver, kidney, and heart, reflecting its role in systemic detoxification. These findings underscore the enzyme's dual role in both protecting tissues and modulating pharmacological efficacy.

CBR1 antibody is applicable in western blotting, immunohistochemistry, and enzymatic activity assays. Western blotting demonstrates isoform expression across tissues, while immunohistochemistry reveals cytosolic distribution. Activity based assays combined with CBR1 antibody confirm enzyme function and response to inhibitors. These approaches allow detailed mapping of metabolic pathways influenced by Carbonyl reductase 1.

By providing validated CBR1 antibody reagents, NSJ Bioreagents supports research into drug metabolism, pharmacogenetics, and detoxification pathways. Detection of Carbonyl reductase 1 offers insights into how cellular defenses interact with therapeutic agents and environmental exposures.

UniProt: P16152